Today: 7 February 2026
Subscribe

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Background and Pipeline Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein (transthyretin) in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 (nexiguran ziclumeran) for transthyretin amyloidosis (ATTR) and NTLA-2002 (lonvoguran ziclumeran) for hereditary angioedema (HAE) ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to
9 October 2025
·
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Import Fair 2025: Turning Imports into Local Industry Uzbekistan’s capital Tashkent buzzed with business activity as the country opened the First International Uzbek Import Fair 2025. The exhibition, held at the Uzexpocentre on October 7–9, is a cornerstone of President Shavkat Mirziyoyev’s industrial strategy to boost local production. Deputy PM Jamshid Khodjaev, inaugurating the fair, emphasized its mission to deepen industrial cooperation, support domestic manufacturers, and promote import substitution uzdaily.uz. The theme “Optimizing Imports and Increasing Local Content” underscores a shift in policy: instead of curbing imports via tariffs or bans, Uzbekistan wants to partner with foreign firms to produce
9 October 2025
United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

Stock Price & Recent Performance As of market close Oct 8, 2025, UAL traded around $98.09 reuters.com, a ~1.5% gain for the day. In early pre-market Oct 9, it had jumped ~6% to ~$104 stockanalysis.com. Over the past week, UAL shares have rebounded from recent lows near ~$94 (Oct 2) to fresh highs around $99–100. The stock’s 6-month chart shows a rally to a mid-September peak (~$109) followed by a pullback; current technical indicators (see below) suggest mild momentum. UAL trades well above its pandemic lows and has outperformed some broader indices this year (its 52-week high is $116 reuters.com).
9 October 2025
·
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Company Overview: A Near-Patient Diagnostics Specialist Bluejay Diagnostics, Inc. is a small Massachusetts-based medical diagnostics company focused on rapid near-patient testing solutions for critical care settings stocktitan.net. The company’s mission is to improve emergency and intensive care outcomes by enabling faster, point-of-care testing for life-threatening conditions like sepsis stocktitan.net. Bluejay’s flagship product-in-development is the Symphony system – an automated, “sample-to-result” analyzer that uses disposable cartridges to measure key biomarkers from a patient’s blood sample in minutes bluejaydx.com bluejaydx.com. Symphony’s first target analyte is interleukin-6 (IL-6), an inflammatory marker that rises during infection and sepsis. In hospitals today, diagnosing sepsis early
9 October 2025
··
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

Latest News (Oct 7–Oct 9, 2025) Stock Performance & Technical Analysis After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ($3.97 – $10.87) ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago (amid a broader biotech downturn) ts2.tech. Such dramatic swings
9 October 2025
···
American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

Stock Price and Recent Performance American Airlines’ stock has been on a turbulent ride in 2025. After starting the year in the high teens, AAL has sunk into the low double-digits – recently closing around $11.81 marketbeat.com. The slide accelerated in September amid soft travel demand and pessimistic guidance. As of early October, shares were down over 34% year-to-date (vastly underperforming the S&P 500) and about 15% lower in the past month alone marketbeat.com. This steep drop reflects both company-specific challenges and broader sector headwinds (from rising costs to economic jitters). This week, however, brought a glimmer of relief. American’s
9 October 2025
··
Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Latest News & Developments (October 2025) Serve Robotics grabbed headlines this week with a major new partnership announcement. On October 9, 2025, the company revealed a deal with DoorDash to deploy Serve’s sidewalk delivery robots for food orders on the DoorDash platform investing.com. Initially rolling out in Los Angeles, the pilot means DoorDash customers from select restaurants may have their meals delivered by a Serve robot investing.com. This is a strategic expansion beyond Serve’s exclusive relationship with Uber Eats to date. “This partnership enables us to go to cities where DoorDash is the dominant player… we’re looking for more demand,
9 October 2025
·
Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Gold Hits $4,000 Record, Silver Soars to $50 – Rally to Continue or Crash Ahead?

Precious Metals Skyrocket to Historic Highs Gold and silver have been on a record-breaking tear in 2025. Gold entered the year around $2,800 and by October blasted past the $4,000/oz milestone – an unprecedented level ts2.tech ts2.tech. On October 7–8, spot gold surged to an all-time high near $4,078 before settling around $4,038 by Oct. 9 ts2.tech reuters.com. This ~53% year-to-date jump is gold’s steepest annual gain since 1979 reuters.com, vastly outpacing equities (the S&P 500 is up ~15% YTD) ts2.tech. “$4,000 an ounce seemed far-fetched at the start of the year… but after a ~50% rally, here we are,”
9 October 2025
·
Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

Jefferies Scrambles as First Brands’ $10 Billion Bankruptcy Reveals $2.3 Billion in ‘Vanished’ Debt

First Brands’ Debt-Fueled Rise and Spectacular Fall First Brands Group’s journey from industry consolidator to bankruptcy cautionary tale was swift and dramatic. The company – a leading supplier of replacement auto parts like oil filters, brake pads and windshield wipers – grew aggressively through debt-financed acquisitions in the 2010s Livemint. By 2025, it owned well-known aftermarket brands such as Raybestos (brake components), TRICO (wiper blades) and FRAM (engine filters), selling through major retailers like Walmart and AutoZone ts2.tech. However, this rapid expansion came at the cost of a towering debt load that far outpaced its earnings. Over the summer of
9 October 2025
···
Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Record Highs Amid a Tech-Fueled Rally Wall Street’s momentum in 2025 is undeniable – and increasingly historic. Stocks have been on a tear, repeatedly smashing records. After seven consecutive daily gains to start October, the market took only a brief pause before charging higher again. On October 8, the S&P 500 and Nasdaq Composite clinched fresh all-time highs (around 6,754 and 23,043 respectively) ts2.tech. These milestones extend what has already been a remarkable year; the S&P is up roughly 18% year-to-date, with the Nasdaq not far behind ts2.tech. Even the blue-chip Dow Jones Industrial Average, while slightly lagging, is near
9 October 2025
·
Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

Nvidia’s $2B Bet on Reflection AI Shakes Up the Global AI Race

Reflection AI’s $2B Funding Frenzy It’s official: Reflection AI has secured one of the largest funding rounds ever for a young tech startup – $2 billion in fresh capital led by Nvidia techmeme.com. The New York Times first reported the blockbuster raise, valuing the one-year-old company at roughly $8 billion techmeme.com. To put that in perspective, Reflection was valued at only ~$545 million as recently as March techmeme.com. In other words, its paper valuation has leapt nearly 15× in just six months, a virtually unheard-of jump. The NYT called this “the latest sign of investor fervor” around AI, even as
9 October 2025
···
Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed, Inc. (NYSE: WOLF) has seen a stunning reversal in fortune. As of October 9, 2025, the stock trades around $30.36 per share, giving the company a market capitalization of roughly $0.7–0.8 billion reuters.com companiesmarketcap.com. Just weeks ago, Wolfspeed emerged from Chapter 11 bankruptcy after cutting its debt by ~70% and interest costs by ~60% ts2.tech. This financial restructuring wiped out most of the old equity – existing shareholders were left with only ~3–5% of the reorganized company ts2.tech – but set the stage for a dramatic stock rally. In fact, WOLF exploded over 1,000% intraday on September 29, 2025
9 October 2025
·
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the most challenging-to-treat solid tumors are treated” by harnessing patients’ own T-cells and genetically equipping them to target cancer cells Adaptimmune. Adaptimmune’s proprietary platform, known as SPEAR T-cells (Specific Peptide Enhanced Affinity Receptor), allows it to design TCRs that recognize tumor-specific antigens (such as MAGE-A4 or NY-ESO-1) and arm patient T-cells with these receptors ts2.tech ts2.tech. In effect, it’s analogous to
9 October 2025
Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari in the Headlines: New Strategic Plan & Stock Shock In early October 2025, Ferrari N.V. held a high-profile Capital Markets Day (investor day) in Maranello, unveiling its 2030 strategic plan and updated guidance. The event proved dramatic – Ferrari’s stock plunged nearly 12% in its worst single-day drop since the company’s 2015 IPO reuters.com. Shares were briefly halted after sliding by double-digits on October 9 reuters.com, and ultimately closed the day deep in the red. This sell-off was sparked by a mix of surprising strategic pivots and cautious long-term targets that rattled some investors, despite Ferrari simultaneously raising near-term
9 October 2025
··
Ethereum $5,000 Soon? Fed Cuts, Small-Cap Rally & Whale Moves Fuel Bold Forecasts

Ethereum $5,000 Soon? Fed Cuts, Small-Cap Rally & Whale Moves Fuel Bold Forecasts

Ethereum Rebounds Toward All-Time Highs Ethereum’s price is once again flirting with record territory after a volatile few weeks. The world’s second-largest crypto came within ~$200 of its all-time high in early October decrypt.co. In late August, ETH actually set a new peak around $4,946 – finally eclipsing its 2021 high – before a sharp September correction decrypt.co. By September 25, Ethereum had plunged below $4,000 amid a broader crypto slump ts2.tech. This pullback rattled some investors (one whale address famously lost $45 million during the dip ts2.tech) but proved short-lived. By early October, ETH regained momentum, climbing back into
9 October 2025
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approvedreuters.com. By then, the landscape may include other new NASH therapies (possibly Lilly’s or Madrigal’s), but Novo’s combination strategy could set it apart. Wolfe Research analyst Andy Chen recently said the field has reached a “meaningful tipping point” as the first therapies emerge, predicting the leading NASH drug could see $5 billion+ in annual sales under broad useinvesting.com. Novo’s own management clearly shares that optimism – they characterize EFX
9 October 2025
PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

Key Data & Metrics (as of October 9, 2025) Metric Value Stock Price (Oct 8, 2025) $138.84 (close)marketbeat.comDown ~6% in past month; ~–6% YTDfinviz.comindexbox.io 52-Week Range Low $127.60 – High $177.48markets.businessinsider.com Market Capitalization ~$193 Billionmarkets.businessinsider.com Forward P/E (2025E) ~17.5× (near industry avg ~17.5×)finviz.com Trailing P/E (TTM) ~21.8×markets.businessinsider.com PEG Ratio (Forward) ~3.5 (industry ~2.3)finviz.com Annual Dividend $5.69 per share (yield ~4.0%)macrotrends.net Dividend Growth 53 years consecutive increases (5% hike in 2025)pepsico.com Q3 2025 Revenue $23.94 B (+2.6% YoY)investing.com Q3 2025 Adjusted EPS $2.29 (beat est. $2.26; –1.7% YoY)investing.comfinviz.com 2025 Full-Year Forecast Low-single-digit organic rev growth; Core EPS ~flat YoYinvesting.com Analyst Consensus Hold (21
9 October 2025
·
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s Strong Quarter Signals a Turnaround Tilray Brands kicked off its fiscal 2026 with better-than-expected results, signaling that aggressive cost-cutting and diversification efforts are bearing fruit. The company’s Q1 FY2026 revenue hit $209.5 million, a 5% increase over last year’s quarter stocktitan.net. More impressively, Tilray managed to swing to a net profit of $1.5 million (or $0.00 per share) – a stark improvement from the -$34.7 million loss in the prior-year period stocktitan.net stocktitan.net. This marks one of Tilray’s first profitable quarters since its 2018 IPO, a milestone achieved through tighter operational discipline. Adjusted EBITDA came in at $10.2 million
9 October 2025
·
Delta Air Lines Stock Takes Off on Strong Earnings and Upbeat Outlook

Delta Air Lines Stock Takes Off on Strong Earnings and Upbeat Outlook

Stock Performance and Recent Price Action Delta’s stock has been on the move following its latest earnings. As of October 9, 2025, DAL trades around $60 per share after spiking about 5–6% on the Q3 reporttradingview.com. This marks a sharp rebound from the mid-$50s levels seen earlier in the week. Over the past week, the stock ranged roughly $56–$58 and is now up slightly week-over-week, bucking a broader market lull. Even after this rally, Delta’s share price remains ~5.6% lower year-to-datetradingview.com, underperforming the S&P 500, which makes the renewed momentum particularly noteworthy. The company’s market capitalization stands near $37–38 billion, making it one of the largest U.S. airlinesgurufocus.com. Notably,
9 October 2025
··
Delta’s Profits Take Off as Travel Demand Soars – Airline Signals Record Holiday Season Ahead

Delta’s Profits Take Off as Travel Demand Soars – Airline Signals Record Holiday Season Ahead

Delta Delivers Soaring Q3 Results Delta Air Lines kicked off airline earnings season with a strong September-quarter performance that blew past projections. The carrier earned $1.42 billion in net income for Q3 2025 – almost 60% higher than the year-ago period – translating to $2.17 per share (GAAP) marketscreener.com. Excluding one-time items, Delta’s profit was $1.71 per share, comfortably above the ~$1.52 analysts expected marketscreener.com. Revenue for the quarter reached $16.67 billion, beating forecasts (~$15.8 billion) and marking a ~8% increase year-on-year marketscreener.com. These results came in at the top end of management’s guidance, as Delta benefited from robust travel demand over the
9 October 2025
1 … 1,469 1,470 1,471 1,472 1,473 … 1,633

Stock Market Today

Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

Data Center Stocks Surge Into the Weekend: Digital Realty, Equinix and Vertiv Set Up a Big Week Ahead

7 February 2026
Digital Realty, Equinix, and Vertiv shares surged Friday, with Vertiv up 10% and Digital Realty rising 4.1%, as investors rotated back into AI-linked data center stocks. The move followed Amazon’s $200 billion and Alphabet’s $175–185 billion 2026 capex targets. Digital Realty set 2026 core FFO guidance at $7.90 to $8.00 per share. Wall Street ended the week broadly higher, led by chipmakers.
Quantum computing stocks bounce hard: IonQ, Rigetti, D‑Wave rally as traders reset for a data-heavy week

Quantum computing stocks bounce hard: IonQ, Rigetti, D‑Wave rally as traders reset for a data-heavy week

7 February 2026
IonQ, Rigetti, D‑Wave, and Quantum Computing Inc shares surged 15–21 percent Friday, erasing losses from the previous session. The rebound followed a Wall Street rally that sent the Dow above 50,000 for the first time. IonQ remains under scrutiny after a short-seller report questioned its Pentagon contract revenue. Investors await delayed U.S. jobs and inflation data next week.
Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

7 February 2026
U.S. space and defense stocks rose Friday, with sector ETFs gaining up to 4.8% and Lockheed Martin up 2.4%. Investors are awaiting a Pentagon list that could restrict buybacks and dividends at underperforming contractors under a Trump executive order. Companies named would have 15 days to submit remediation plans. Lockheed’s board approved a $3.45 per share dividend for Q1 2026.
Go toTop